Cargando…
Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
BACKGROUND: Exon skipping has been considered a promising therapeutic approach for Duchenne muscular dystrophy (DMD). Eteplirsen received conditional approval in the United States in 2016. To date, no systematic reviews or meta-analyses of randomized controlled trials (RCTs) of exon skipping drugs h...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003096/ https://www.ncbi.nlm.nih.gov/pubmed/29907124 http://dx.doi.org/10.1186/s13023-018-0834-2 |